



Mass spectrometry-based intraoperative tumor diagnostics: a letter in reply

Isabelle Fournier, Michel Salzet

► To cite this version:

Isabelle Fournier, Michel Salzet. Mass spectrometry-based intraoperative tumor diagnostics: a letter in reply. Future Science OA, 2019, 5 (7), pp.FSO403. 10.2144/fsoa-2019-0037 . inserm-02941629

HAL Id: inserm-02941629

<https://inserm.hal.science/inserm-02941629>

Submitted on 17 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Mass spectrometry-based intraoperative tumor diagnostics: a letter in reply

Isabelle Fournier^{*,1} & Michel Salzet^{**,1} 

¹Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Université de Lille, Inserm U1192 - Laboratoire Protéomique, F-59655 Villeneuve d'Ascq Cedex, France

*Author for correspondence: Isabelle.fournier@univ-lille.fr

**Author for correspondence: Tel.: +33 320 434 194; Michel.salzet@univ-lille.fr

First draft submitted: 20 March 2019; Accepted for publication: 23 May 2019; Published online: 1 August 2019

Keywords: cancer • guided surgery • intraoperative tumor diagnostics • real-time diagnosis • SpiderMass • surgery • tumor margin

We wish to offer our perspective and expertise concerning the review article entitled ‘mass spectrometry-based intra-operative tumor diagnosis’ written by Lorena Hänel *et al.* in *Future Science OA*. We were struck reading this article by the fact that the authors did not properly address the state-of-the-art of the field in their review and were not addressing all the technologies developed over the past years to address intraoperative tumor diagnostic by MS. As a matter of fact, the authors fail to mention the SpiderMass technology. Therefore, they provide inadequate and not up-to-date citation on this discussed topic. In 2014, PRISM lab (Lille, France) introduced the water-assisted laser desorption/ionization MS (SpiderMass) and filed the patent (PCT/IB2015/057301) [1]. Similar to iKnife [2] and MassSpec Pen [3], the SpiderMass constitutes a micro-sampling probe, transfer line and MS analyzer. The system is based on laser ablation in the infrared (IR) wavelength tuned to excite the most intense vibrational band (O–H) of water molecules, called water-assisted laser ionisation/desorption process. The water constitutes an average 70–80% of the tissues in the human body, and can act as an endogenous matrix and provide analyte ionization as in conventional MALDI [4]. After the laser ablation, ions are collected using the MS vacuum via polymeric tubing positioned just above the analyzed tissue and connected directly to the inlet of the MS source. In this way, the aerosol is delivered to the analyzer, without the need of post-ionization device. As a result, the molecular profiles of ablated tissue are acquired, and can be further compared with a databank containing recorded *ex vivo* molecular profiles of a cohort of biopsies for example. One of the major advantages of the SpiderMass system is its low invasiveness and painless sampling, tissues being reversibly dehydrated. Another advantage and specific characteristic of SpiderMass is the very low fragmentation observed in the spectra and the possible operation in both positive and negative ion modes with good sensitivity. The system was successfully applied for cancer biopsies analysis *ex vivo* and then was shown for allowing real-time analysis of human skin *in vivo* as presented for the first time in 2015 at the ASMS conference and then published in 2016 [5]. The publication evidently shows the first use of a laser-based system coupled to a mass spectrometer for *in vivo* analysis and its potential to be used in intraoperative diagnostics. Over the past few years, the system was used to analyze genetically modified macrophage cell lines [6] as well as intact proteins. The latest publication in 2018 showed the analysis of dog sarcoma samples *ex vivo*, allowing for correct classification (97% of specificity) of tumor type and grading [7]. Furthermore, the system demonstrated its applicability for *in vivo* intraoperative analysis at the surgery room in a veterinary clinic on dog patients [7]. A recent publication in Cancer Cell by Dr Emily Z Keung and Christina L Roland, from the Department of Surgery Oncology of The University of Texas MD Anderson Cancer Center, acknowledged this work and mentioned the SpiderMass system as a step forward in the right direction for molecular cancer diagnostics [8]. The aforementioned examples clearly show that the PRISM Laboratory with its SpiderMass technology is one of the important research groups developing MS-based intraoperative diagnostics [9].

Acknowledgments

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

References

1. Salzet M, Fournier I, Focsa C, Ziskind M, Fatou B, Wisztorski M. Device for real-time *in vivo* molecular analysis. Google Patents (2017). <https://patents.google.com/patent/CA2961491A1/en?q=salzet&inventor=fournier&coq=fournier+and+salzet>
2. Schafer KC, Denes J, Albrecht K *et al.* *In vivo, in situ* tissue analysis using rapid evaporative ionization mass spectrometry. *Angew. Chem. Int. Ed. Engl.* 48(44), 8240–8242 (2009).
3. Zhang J, Rector J, Lin JQ *et al.* Nondestructive tissue analysis for *ex vivo* and *in vivo* cancer diagnosis using a handheld mass spectrometry system. *Sci. Transl. Med.* 9(406), eaan3968 (2017).
4. Fournier I, Fatou B, Wisztorski M, Focsa C, Ziskind M, Salzet M. Development of a novel instrument for *ex-vivo* and *in-vivo* real-time analysis. *J. Biotechnol.* 208, S10 (2015).
5. Fatou B, Saudemont P, Duhamel Met *et al.* Real time and *in vivo* pharmaceutical and environmental studies with 944 SpiderMass instrument. *J. Biotechnol.* 281, 61–66 (2015).
6. Fatou B, Saudemont P, Leblanc E *et al.* *Invivo* real-time mass spectrometry for guided surgery application. *Sci. Rep.* 6, 25919 (2016).
7. Fatou B, Ziskind M, Saudemont P *et al.* Remote atmospheric pressure infrared matrix-assisted laser desorption-ionization mass spectrometry (remote IR-MALDI MS) of proteins. *Mol. Cell. Proteomics* 17(8), 1637–1649 (2018).
8. Saudemont P, Quanico J, Robin Y-M *et al.* Real-time molecular diagnosis of tumors using water-assisted laser 942 desorption/ionization mass spectrometry technology. *Cancer Cell* 34, 840.e4–851.e4 (2018).
9. Keung EZ, Roland CL. Accurate and reproducible diagnosis of canine soft tissue sarcoma using mass spectrometry: a step in the right direction. *Cancer Cell* 34(5), 697–699 (2018).
10. Hanel L, Kwiatkowski M, Heikaus L, Schluter H. Mass spectrometry-based intraoperative tumor diagnostics. *Future Sci. OA* 5(3), FSO373 (2019).